Harrow (HROW) Scheduled to Post Earnings on Monday

Harrow (NASDAQ:HROWGet Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, May 13th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Harrow (NASDAQ:HROWGet Free Report) last issued its earnings results on Tuesday, March 19th. The company reported ($0.27) EPS for the quarter. Harrow had a negative return on equity of 29.48% and a negative net margin of 18.75%. The firm had revenue of $36.36 million for the quarter, compared to analyst estimates of $37.65 million. On average, analysts expect Harrow to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Harrow Stock Up 12.7 %

Harrow stock opened at $11.60 on Friday. The stock’s fifty day moving average is $11.42 and its two-hundred day moving average is $10.92. The company has a debt-to-equity ratio of 2.60, a current ratio of 2.83 and a quick ratio of 2.61. The stock has a market cap of $410.41 million, a PE ratio of -15.47 and a beta of 0.58. Harrow has a 1-year low of $7.60 and a 1-year high of $27.80.

Wall Street Analyst Weigh In

HROW has been the subject of several recent analyst reports. B. Riley reduced their price objective on shares of Harrow from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, March 22nd. Craig Hallum started coverage on Harrow in a report on Thursday, April 11th. They set a “buy” rating and a $24.00 price objective on the stock.

Read Our Latest Analysis on Harrow

Insiders Place Their Bets

In other news, CEO Mark L. Baum acquired 9,000 shares of the stock in a transaction that occurred on Friday, March 22nd. The shares were purchased at an average cost of $11.59 per share, for a total transaction of $104,310.00. Following the transaction, the chief executive officer now directly owns 2,137,525 shares in the company, valued at approximately $24,773,914.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Harrow news, CEO Mark L. Baum bought 9,000 shares of the business’s stock in a transaction dated Friday, March 22nd. The stock was acquired at an average cost of $11.59 per share, with a total value of $104,310.00. Following the purchase, the chief executive officer now owns 2,137,525 shares in the company, valued at approximately $24,773,914.75. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Opaleye Management Inc. purchased 50,600 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The stock was acquired at an average price of $9.65 per share, for a total transaction of $488,290.00. Following the completion of the purchase, the insider now owns 3,695,600 shares of the company’s stock, valued at $35,662,540. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 170,715 shares of company stock valued at $1,864,011. Insiders own 13.60% of the company’s stock.

Harrow Company Profile

(Get Free Report)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Featured Articles

Earnings History for Harrow (NASDAQ:HROW)

Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.